Health care utilization for psoriasis in the United States differs by race: An analysis of the 2001-2013 Medical Expenditure Panel Surveys - 13/12/17
![](/templates/common/images/mail.png)
Dr Takeshita is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K23-AR068433. Dr Gelfand is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K24-AR064310. |
|
In the previous 12 months, Dr Gelfand has served as a consultant for Coherus (DSMB), Dermira, Janssen Biologics, Merck (DSMB), Novartis, Regeneron, Sanofi, and Pfizer, receiving honoraria, and he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Regeneron, Sanofi, Celgene, and Pfizer, and received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and AbbVie. Dr Gelfand is a co–patent holder of resiquimod for the treatment of cutaneous T cell lymphoma. Dr Takeshita has received a research grant from Pfizer (to the Trustees of the University of Pennsylvania) and payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly. The other authors have no conflicts of interest to declare. |
Vol 78 - N° 1
P. 200-203 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?